Neuroimmune mechanisms in fear and panic pathophysiology

Katherine M. J. McMurray1,2* and Renu Sah1,2

1Department of Pharmacology and Systems Physiology, University of Cincinnati, Cincinnati, OH, United States, 2Veterans Affairs Medical Center, Cincinnati, OH, United States

Panic disorder (PD) is unique among anxiety disorders in that the emotional symptoms (e.g., fear and anxiety) associated with panic are strongly linked to body sensations indicative of threats to physiological homeostasis. For example, panic attacks often present with feelings of suffocation that evoke hyperventilation, breathlessness, or air hunger. Due to the somatic underpinnings of PD, a major focus has been placed on interoceptive signaling and it is recognized that dysfunctional body-to-brain communication pathways promote the initiation and maintenance of PD symptomatology. While body-to-brain signaling can occur via several pathways, immune and humoral pathways play an important role in communicating bodily physiological state to the brain. Accumulating evidence suggests that neuroimmune mediators play a role in fear and panic-associated disorders, although this has not been systematically investigated. Currently, our understanding of the role of immune mechanisms in the etiology and maintenance of PD remains limited. In the current review, we attempt to summarize findings that support a role of immune dysregulation in PD symptomology. We compile evidence from human studies and panic-relevant rodent paradigms that indicate a role of systemic and brain immune signaling in the regulation of fear and panic-relevant behavior and physiology. Specifically, we discuss how immune signaling can contribute to maladaptive body-to-brain communication and conditioned fear that are relevant to spontaneous and conditioned symptoms of PD and identify putative avenues warranting future investigation.

KEYWORDS
panic, fear, neuroimmune, panic disorder, interoception, body-to-brain

Introduction

A complex interplay and engagement of the central nervous system (CNS) and periphery is key to the genesis of emotional responses (1). Peripheral modulation of the-emotional responses was first postulated early under the peripheral feedback theory by William James (2) and later championed as interoceptive emotional modulation by several investigators (3, 4). Dysregulated interoceptive processing and maladaptive
emotional responses are a hallmark of fear-associated disorders, particularly Panic Disorder (PD), a debilitating psychiatric illness which occurs in ∼4–8% of Americans (5–7). PD typically begins in the second decade of life (8) and is second only to major depressive disorder in terms of associated debility among psychiatric conditions in the United States (9). PD is characterized by recurrent panic attacks that consist of incapacitating periods of acute-onset respiratory, cardiovascular, gastrointestinal autonomic, and cognitive symptoms. According to the DSM-5 (10), recurrent panic attacks in PD are categorized as being either spontaneous (unexpected) or cued (expected). Recurrence of panic attacks leads to anticipatory anxiety, conditioned fear and avoidance of panic contexts, cues and reminders leading to compromised functioning and disability (11–15). Current treatments have limited therapeutic efficacy and a delayed onset of action (15–17). While studies in the past few decades have improved our understanding of panic neurobiology [reviewed in: (18–20)], the mechanistic basis of spontaneous panic and sustained fear is still poorly understood yet could lead to improvements in treatment outcomes.

The association of PD with dysregulated interoceptive processing suggests an important role for body-to-brain signaling in PD pathology. While body-to-brain signaling can occur via several pathways, immune and humoral pathways play an important role in communicating bodily physiological state to the brain (21). Immune activation in conjunction with humoral interoceptive mechanisms can mediate discrete changes in brain and behavior that may predispose to psychiatric disorders (21–24). Strong evidence supports a role for the immune system and associated cellular mediators in regulation of behaviors associated with depression and anxiety such as sickness behavior, anhedonia and learned helplessness [reviewed in (22–25)]. Accumulating evidence suggests that neuroimmune regulatory mechanisms also play a role in fear and panic-associated disorders, although this has not been well studied. Interestingly, mounting epidemiological evidence supports a high comorbidity of PD with inflammatory conditions such as Crohn’s disease, asthma, inflammatory bowel syndrome (IBS) and fibromyalgia (26–31), suggesting a potential role of dysregulated immune signaling in PD pathology. However, our understanding of the role of immune mediators in the etiology and maintenance of PD remains limited.

Thus, in the current review, we attempt to summarize findings that support a role of immune dysregulation in PD symptomology. We compile evidence from human studies and panic-relevant rodent paradigms that indicate a role of systemic and brain immune signaling, in the regulation of fear and panic-relevant behavior and physiology. Specifically, we discuss how immune signaling can contribute to maladaptive body-to-brain communication and conditioned fear that are associated with spontaneous and conditioned aspects in PD onset and maintenance.

Relevance of interoception and conditioned fear in panic disorder

Clinical observations and collective evidence from challenge studies in the laboratory, neuroimaging, symptomology, treatment responses and translational animal models have led to an increased understanding of PD (11, 12, 14, 18–20, 32–41). As illustrated in Figure 1, PD frequently originates with patients experiencing spontaneous panic attacks that seem to occur without an explicit trigger. Over time, PD develops as the result of associative conditioning processes that lead to fear and phobic avoidance as well as anticipatory anxiety of future attacks (15). Thus, to improve our understanding of PD and develop novel treatments, clinical and preclinical work has sought to understand the mechanisms underlying these various aspects of panic pathology, including both spontaneous panic attacks and attacks driven by conditioned responses, as well as the relationship between these processes.

Panic disorder is highly heterogeneous with variable symptom profile and intensity in panic episodes experienced by the same individual and across patients (14, 15, 42). Interestingly, PD is unique among anxiety disorders in that fear and anxiety associated with panic are primarily directed toward somatic symptoms (32). In these individuals, body sensations or physiological signals linked to risk of suffocation (e.g., dyspnea, breathlessness, or air hunger) elicit dysfunctional defensive responding leading to anxious apprehension, fear, panic, contributing to the persistence of PD symptomatology. Due to the somatic underpinnings of PD, a major focus has been placed on interoceptive signaling and body-to-brain communication pathways, as interoceptive inputs serve an important regulatory function in generation of adaptive behaviors and physiology key to emotional regulation (3, 4, 37). Indeed, strong evidence now supports a primary role of homeostasis and interoception “an individual’s sensing and monitoring of the physiological condition of the body itself” in driving panic attacks (3, 4, 37, 43). In particular, it has been proposed that while the expected or cued panic attacks in PD are triggered by exteroceptive triggers (i.e., context of previous panic attack or other unrelated stressors, or traumatic experiences), the unexpected or spontaneous panic attacks may be provoked by interoceptive sensory triggers caused by fluctuations in the internal milieu that challenge homeostasis (37).

This theory of interoceptive signaling driving PD is primarily based on observations that patients with PD show heightened sensitivity to homeostatic disturbances, particularly those that induce acidosis such as CO₂ inhalation and sodium lactate infusion (18, 38, 40, 44–62). In people with PD, these threats to internal homeostasis drive increased fear, respiratory, and cardiac responses that can result in panic attacks, suggesting this heightened sensitivity may confer vulnerability to panic attacks (38, 58). The ability to evoke panic attacks in clinical populations within the lab has greatly improved our
FIGURE 1
The cycle of panic disorder: Vulnerability factors such as genetic predisposition, early life adversity, chronic illness, physiological state (i.e., dehydration), or other psychiatric disorder diagnosis associate with innate sensitivity to homeostatic triggers. These homeostatic triggers are threats to internal homeostasis that lead to a heightened state of alarm, the activation of threat responses systems and a panic attack. The emotional, behavioral and physiological responses occurring during panic attacks such as fear, anxiety, hyperventilation and cardiovascular responses are evoked in an effort restore physiological homeostasis. The engagement of these systems and the conditioned responses to contexts where panic attacks occurred can lead to hypersensitivity to future homeostatic triggers, novel stressors or trauma, and exposure to previous panic contexts. This can lead to a cycle of recurrent panic attacks, and anticipatory anxiety and avoidance of panic-associated contexts, that ultimately facilitates the development of panic disorder.

understanding of the behavioral, emotional and physiological aspects of panic attacks. It has also allowed researchers to investigate the effects of pharmacological treatments or other therapies (i.e., cognitive behavioral therapy, etc.). Additionally, it has allowed for quantification of molecular biomarkers within blood or saliva immediately before and after panic attacks.

CO$_2$ inhalation is the interoceptive stressor most commonly used to probe the mechanisms underlying panic attacks and PD. In this model, individuals are exposed to either low-dose CO$_2$ inhalation (5–7.5% CO$_2$) or a single beath of high-dose 35% CO$_2$ by breathing in air composed of non-hypoxic levels of oxygen (~21%) and varied nitrogen levels used to balance differing CO$_2$ percentages (19, 34, 38, 45, 46, 49, 55, 56, 58, 59, 63, 64). CO$_2$ inhalation evokes fear, anxiety and physiological responses in both patients with PD and in healthy individuals (38, 45, 46, 55). Responses to CO$_2$ inhalation increase in intensity as the concentration of CO$_2$ increases and tend to be stable across time (53). Interestingly, CO$_2$ sensitivity seems to lie on a spectrum. Compared to individuals without PD, patients with PD show a left-shifted CO$_2$ inhalation response curve, presenting with heightened emotional and physiological responses, and a greater likelihood of a resultant panic attack across all CO$_2$ inhalation concentrations. First-degree family members of patients with PD present with an intermediate CO$_2$ sensitivity phenotype between healthy individuals and those with PD suggesting there may be a genetic influence on this phenotype (38). Although not clearly defined, predisposition factors associated with PD such as genetics, early life adversity, underlying respiratory abnormalities and other factors are thought to promote sensitivity to interoceptive stressors like CO$_2$ inhalation (18, 20, 52, 53, 61, 65, 66). Given the strength of the association between sensitivity to interoceptive stressors and PD, studies seeking to understand the mechanisms driving CO$_2$ sensitivity may improve our understanding of PD and lead to identification of novel treatments.

Although spontaneous panic attacks are key to panic etiology, the development to PD also involves associative conditioning processes leading to fear and phobic avoidance (15, 32, 37, 67, 68). This can be particularly detrimental to quality of life in patients as they begin to avoid situations or contexts they believe may elicit panic attacks. Studies exploring conditioned fear responses, particularly contextual associations, have improved our understanding of PD and aided the development of behavioral therapies (32, 37, 67, 68). Studies investigating the transition from initial spontaneous panic attacks to development of conditioned fear are more limited yet understanding this transition may improve our ability to prevent the development of PD or improve treatments. Previous evidence suggests that initial panic attacks associated with dysfunctional interoceptive body-to-brain signaling could lead to sensitized fear-arousal-stress regulatory circuits to promote the chronicity and maintenance of PD (see Figure 1).
Interestingly, IL-10 inhibits the nearly ubiquitous expression of several inflammatory cytokines (80, 81). Protective role in reducing the manifestations of PD in female patients was reported that the G allele in IL-10-1082 G/A might have a protective role in reducing the manifestations of PD in female patients (79). The group reported that pathways related to immunity show the strongest association with PD. For further investigation, the group studied HLA polymorphisms in candidate susceptibility genes HLA-B and HLA-DRB1, associated with the major histocompatibility complex (MHC) and immune dysfunction in PD patients and control subjects (88). Patients with PD were significantly more likely to carry HLA-DRB1 further supporting links to immune regulation and genes involved in immune-related pathways are associated with PD.

In addition to gene polymorphism and pathway analysis studies, epigenetic contributions have been investigated in the context of immune modulation. A recent study investigated whether aberrant DNA methylation of inflammation-related genes was associated in the development of PD (90). Methylation levels of CCL3, CRP, CSF2, CXCL8, IFNG, IL12B, IL1A, IL-4, IL-6, TNF was investigated. Significantly higher methylation levels of the IL-4 gene were observed in PD patients than control subjects. Importantly, the methylation levels of IL-4 gene showed a significant positive correlation with the severity of panic and anxiety (90). In another study, a significant association between panic severity score and methylation levels of Asb1, a member of the suppressors of cytokine signaling (SOCS) family was observed in PD subjects, suggesting a role of epigenetic factors. Furthermore, in a follow up mouse study, the authors found a correlation between peripheral Asb1 and IL-1β mRNA expression after acute social defeat stress suggesting a relationship between Asb1, IL-1β and stress responding (91). Assessment of T cell receptor excision circles (TRECs), Forkhead-Box-Protein P3 gene (FOX3P) methylation of regulatory T cells (Tregs) and relative telomere lengths (RTLs) was conducted in patients with PD and age- and sex-matched healthy controls in order to test for a potential dysfunction and premature aging of the immune system (92). Significantly reduced TRECs in PD patients and FOX3P hypermethylation

Immune contributions in panic and fear: Clinical evidence

Mounting evidence from the clinic supports a potential role of dysregulated immune function in PD. Most work has focused on identifying specific genes, epigenetic associations or alterations in immune effectors comparing individuals with PD to those without a PD diagnosis that we will discuss below:

1) Immune-associated genes in Panic Disorder

Genetic studies indicate a heritability of PD at about 40% (78) suggesting a strong role for genetic variance in mediating risk to develop PD. Identifying the specific genes or gene clusters (groups of genes involved in similar functions or pathways) associated with PD could help improve our understanding of the mechanisms underlying PD and point to putative therapeutic targets. Multiple genetic studies have identified associations between immunomodulatory genes and PD. Single nucleotide polymorphisms (SNPs) within the INF-γ (+ 874 A/T), TNF-α (-308 G/A), and IL-10 (-1082 G/A) genes were investigated in patients with PD (79). The group reported that the G allele in IL-10-1082 G/A might have a protective role in reducing the manifestations of PD in female patients. IL-10 is an anti-inflammatory cytokine inhibiting the generation of several inflammatory cytokines (80, 81). Interestingly, IL-10 inhibits the nearly ubiquitous expression of indoleamine 2,3-dioxygenase (IDO), an enzyme responsible for directing tryptophan degradation, a pathway that has been implicated in anxiety disorders (82–84). Another study found an association of polymorphisms in the IKBKE (inhibitor of kappa light polypeptide gene enhancer in B cells, kinase epsilon) gene in patients with PD (85). IKBKE is involved in regulation of innate immunity, inhibiting NF-kappa B signaling in response to inflammatory cytokines, particularly IL-1 (85, 86), suggesting a potential role of innate immune signaling in PD. Association of a MASP-2 YA haplotype and Mannan-binding lectin (MBL) deficiency was reported in patients with PD, an observation explained to be associated with innate immune alterations that may increase susceptibility for infections and autoimmune states due to their roles in complement activation (87). In strong support of an immune dysfunction in PD, Shimada-Sugimoto et al. (88), performed pathway analyses in order to overcome the limitations of conventional single-marker analysis in identifying associated SNPs with modest effects. Using multiple pathway analyses the group reported that pathways related to immunity show the strongest association with PD. For further investigation, the group studied HLA polymorphisms in candidate susceptibility genes HLA-B and HLA-DRB1, associated with the major histocompatibility complex (MHC) and immune dysfunction in PD patients and control subjects (89). Patients with PD were significantly more likely to carry HLA-DRB1 further supporting links to immune regulation and genes involved in immune-related pathways are associated with PD.

2) Gene expression studies

Gene expression studies in human PD brains have shown changes in the expression of genes related to immune function. One study found a significant decrease in the expression of the interferon-γ (IFN-γ) gene in PD brains compared to controls, suggesting a potential role of the immune system in the pathophysiology of PD (93). Another study found increased expression of the TNF-α gene in PD brains, which may contribute to the inflammatory response associated with PD (94). These findings suggest that changes in gene expression may contribute to the immune dysfunction observed in PD and have implications for the development of therapeutic strategies targeting immune function.
in female patients with PD was observed, reflecting immune system-related deficits in PD.

Other studies support differences in the expression of immune-associated genes in panic pathology. Our lab found significantly higher expression of immunomodulatory gene T-cell death associated gene 8 (TDAG8) in peripheral monocytes collected from PD subjects and healthy volunteers (93). TDAG8, also expressed in brain microglia, is an acid sensing GPCR regulating CO$_2$-associated fear (94). Interestingly, a significant positive correlation was observed between monocytic TDAG8 expression and panic symptom severity score and TDAG8 expression was lower in individuals with symptom remission, suggesting potential utility of TDAG8 as a treatment response biomarker (93). Lastly, one group, Maron et al. (95) conducted gene expression profiling following cholecystokinin CCK-4, a commonly used panic provocation agent challenge in control subjects. Interestingly, several immune regulatory genes showed alterations between “panickers” and “non-panickers,” suggesting that acute panicogenesis may engage immune system targets.

Collectively, genetic evidence suggests dysregulation of immune function and possibly epigenetic mechanisms in panic etiology. Although some association with immunomodulatory genes have been reported in PD, more follow up investigation is warranted.

2) Immune effectors in PD

Measurement of alterations in immune mediators such as cytokines, chemokines and T cells have been conducted in individuals with PD. Several studies have reported altered cytokine concentrations in PD, however directionality and targets assessed differ between studies and are not always consistent. In general, a broad spectrum of cytokines appear to be upregulated in PD (96, 97) suggesting dysregulated immune signaling, however, specific associations and contribution to panic physiology is not well understood. Due to variability in study layouts and for correct interpretation, we have divided available evidence into measurements performed at baseline (no challenge) or following a panic-relevant challenge or stressor.

i) Immune alterations in panic disorder under non-challenge conditions

Proinflammatory mediators within the interleukin (IL) family have been the most studied in the context of PD with measurements reported on IL-6, IL-1β, IL-2, IL-3, IL-12, IL-10, and TNFα [see (97)]. Multiple studies have shown elevated IL-6 concentrations in the serum of PD subjects (96, 98–100). One study showed that while patients with both PD and generalized anxiety disorder (GAD) showed higher IL-6 compared to healthy individuals, PD subjects had even greater IL-6 than individuals with GAD (98). Interestingly, the utility of IL-6 as a potential treatment response biomarker is supported by significantly lower IL-6 concentrations in individual with remitting symptoms compared to those with current panic symptoms (99). Furthermore, another study observed as association of pretreatment IL-6 with poor treatment response (100). However, other studies have reported no significant changes in IL-6 in PD patients (101, 102), suggesting that factors other than a panic diagnosis may contribute to IL-6 alterations.

The IL-1 family of cytokines have also been investigated in PD. A study by Brambilla et al. (103) measured IL-1β plasma concentrations before and after treatment with alprazolam, and reported significantly higher IL-1β both before and after treatment (103). However, other studies have reported no associations of IL-1α/IL-1β with PD (102, 104). These inconsistencies have been contributed to differences in assay methodologies (97).

C-reactive protein (CRP), an inflammatory marker shows significant elevation in patients with PD as compared to healthy controls (105). Following 8 weeks of selective serotonin reuptake inhibitor (SSRI) treatment, CRP concentrations decreased only in treatment-responsive individuals. Additionally, the authors found reduced γ globulin and higher cortisol levels in PD patients compared to controls prior to initiation of treatment. Collectively, these observations suggest engagement of the acute phase response in PD.

Measurement of broad spectrum panel of cytokines and inflammatory markers such IL–6, IL–1α, IL–1β, IL–8, MCP–1, MIP–1α, Eotaxin, GM–CSF, and IFN–α revealed that 87% of individuals with PD or PTSD had six or more detectable levels of these cytokines, compared with only 25% of control (96). In PD patients compared to controls, 17 of 20 cytokines and chemokines examined showed significant elevation, suggesting that PD may associate with a generalized inflammatory state and that specific “inflammatory signatures” may differ on an individual basis. This could associate with the general heterogeneity in symptomology shown within PD patients.

Among other members of the interleukin family, higher IL-2 concentrations were reported in PD subjects compared to healthy controls by one study (104), however no associations were reported by other studies (101, 102, 106). One study reported increased IL-18 concentrations in PD the magnitude of which was comparable to a concurrently tested group of depression subjects (107).

ii) Immune alterations post stressor in patients with PD

The ability to respond appropriately to stressors and adapt is critical to survival by increasing alertness and preparing the body to fight (108). Engagement of stress responses with the immune system may have originated from a need to prepare the body to fight infection from wounds (109). Mounting evidence suggests that immune system engagement may also regulate fear learning which may be beneficial to survival by
helping an individual remember that a fearful environment should be avoided (109). Immune responses to stressors occur in healthy individuals, but evidence suggests these responses may be dysregulated in those with psychiatric diagnoses (22, 70, 73, 110). As both homeostatic and psychogenic stressors are relevant to panic physiology (Figure 1), investigating immune-associated alterations following panic-relevant stressors in individuals with PD can provide valuable information.

To date, only one study directly studied alterations in immune factors pre- and post -CO₂ inhalation (101), a well-established interoceptive stressor in PD described above. No significant differences in either baseline or post CO₂ concentrations of TNF-α, IL-6, IL-8, IL-10, IL-1RA, soluble sIL-2R, soluble sIL-6R or positive acute phase protein haptoglobin were observed. Lipopolysaccharide-stimulated cytokine production (TNF-α, IL-6, IL-1β, IL-10, IFN-γ) in whole blood was comparable for PD patients and their matched controls. Limitations of the study suggested by the authors included: the low number of subjects and a gender-biased sample with underrepresentation of women. Given the relevance of panic provocation challenges in PD, more larger “n” studies are warranted; not only for CO₂ inhalation, but other interoceptive challenges such as sodium lactate.

Dysfunctional stress response systems such as the hypothalamic pituitary adrenal (HPA) axis and sympathetic nervous system (SNS) have been reported in PD [reviewed in (111)]. These stress response systems have bidirectional regulatory associations with the immune system, with either system engaging the other to regulate immune and stress responses (24, 112–114). Accumulating evidence indicates stress-neuroimmune interactions in anxiety disorders including PD (115). Given strong evidence of immune dysregulation within PD patients under non-stressful conditions, it is important to determine whether immune responses to stressful stimuli are dysregulated and whether immune dysregulation could contribute to CO₂ sensitivity in patients with PD.

Exposure to acute psychological stressors have previously been reported to show engagement with the immune system, particularly cytokine release. For example, public speaking or performing complex tasks in public elevated plasma cytokines and CRP (116–118). One study compared immune mediators in healthy individuals and those with PD following the Trier Social Test (TSST) (119). They found PD patients have higher baseline and post stressor concentrations of IL-10, and also show blunted cortisol responses. Interestingly, peak IL-6 concentration associated with PD symptom severity. Heightened startle responses have also been reported in PD patients compared to healthy controls only under fear-associated threat conditions (120). Interestingly, there is an association between heighted startle reactivity and inflammation (75).

Collectively, evidence suggests altered immune mediators in PD, that may represent underlying immune dysfunction, however, additional studies especially following panic-relevant triggers and stress challenges are required for understanding their association with PD physiology. Human studies are limited and cannot provide mechanistic information on brain neuroimmune alterations and association with panic-relevant behaviors. Furthermore, it is difficult to probe neurocircuits orchestrating body to brain signaling. In the following section, we discuss selected paradigms that may be relevant to understanding the mechanistic association of immune dysregulation and panic associated behavior and physiology.

### Understanding panic-fear-neuroimmune links: Relevant translational models

Several panic-relevant rodent models have been developed over the last few decades that provide valuable insights on panic pathophysiology. Consistent with the importance of uncued/spontaneous and cued triggers in generating behavioral and physiological responses in PD, these models have focused on homeostatic and stress challenges, respectively [reviewed in (18–20, 34, 48, 52, 121–124)]. Previously reviewed literature has primarily focused on acid-base homeostasis, PD-relevant neurotransmitter systems, region-targeted interventions, genetic and transgenic manipulations. Despite emerging evidence from human studies, contribution of immune mechanisms in panic and fear has not been systematically investigated using translational paradigms. In this section, we assess selected rodent paradigms that provide information on the potential role of immune cells, targets and signaling that may regulate panic-relevant responses and provide mechanistic insights on panic-fear-immune links (see Table 1).

1) CO₂ inhalation and microglial acid sensing by TDAG8

As described in preceding sections, homeostatic triggers that promote acid-base imbalance such as low-dose, non-hypoxic CO₂ inhalation induce intense fear, anxiety, physiological responses and panic attacks in PD subjects (18, 19, 34, 38, 41, 47, 56). Several investigators including our laboratory, have used CO₂ inhalation to simulate panic-relevant behavior and physiology in mice and rats (48, 65, 94, 125–133). The partial pressure of CO₂ in the blood and CNS increases following CO₂ inhalation challenge. In the extracellular fluid, CO₂ is hydrolyzed to carbonic acid (H₂CO₃) by carbonic anhydrase which readily dissociates into bicarbonate (HCO₃⁻) and H⁺ (134). The resulting acidosis constitutes a homeostatic threat that is sensed by acid-sensing chemosensors in the brain and periphery (18, 19, 34, 38, 41, 47, 56). This model has strong translational value due to its strong face, predictive and etiological validity [discussed in: (18, 19, 48, 127)].

Given its strong translational value, CO₂ inhalation in rodents is commonly used to investigate mechanisms
### TABLE 1  Animal studies of immune regulation of spontaneous/conditioned fear.

| Model                                | PD-relevant phenotype and effect                              | Potential immune effectors          | Brain region(s) implicated                                                                 | References               |
|--------------------------------------|--------------------------------------------------------------|-------------------------------------|-------------------------------------------------------------------------------------------|--------------------------|
| Panic-relevant (spontaneous)         |                                                              |                                     |                                                                                            |                          |
| CO₂ Inhalation                       | Freezing, respiration, blood pressure                        | TDAG8, IL-1β, IL-1RA                | SFO                                                                                       | Vollmer et al. (94)      |
|                                      | Freezing, rearing                                            | IL-1β, IL-1R1, IL-1RA               | SFO, mPFC, amygdala, PAG                                                                 | McMurray et al. (152)    |
|                                      | Microglia                                                    |                                     | Nucleus tractus solitarius, locus coeruleus                                               | Marques et al. (169)     |
| Panic-relevant (conditioned fear)    | Conditioned fear (freezing), extinction (freezing)          | IL-6                                | Whole brain and hippocampus                                                                | Young et al. (76)        |
| Fear conditioning (FC) (without prior stress; no follow up behavior) | Contextual extinction acquisition (freezing)                 | TNF-α                               |                                                                                           | Yu et al. (203)          |
|                                      | Auditory extinction acquisition (freezing)                  | IFN-α, IL-1β, TNF-α                | Amygdala                                                                                  | Bi et al. (215)          |
|                                      | Extinction acquisition (freezing)                            | IL-6                                | Amygdala                                                                                  | Hao et al. (282)         |
|                                      | Contextual fear extinction (Freezing); Open field (center duration), Elevated Plus Maze (open arm time) | Nlrp3 inflammasome: cleaved Casp1, IL-1β, and TNFα | Hippocampus                                                                             | Dong et al. (204)        |
| Models of panic vulnerability (stressors exacerbating later panic-relevant outcomes) | Early life stressor: neonatal maternal separation | Impaired response to influenza infection: IL-1, IL-6, IL-12, IFN-γ, and TNFα mRNA in lung (IL-1, TNFα and IFNG only in females) corticosterone |                                                                      | Avitsur et al. (228)     |
|                                      | Open field (center time), forced swim test (immobility)      | CD8⁺ T cells, spleen T cell         |                                                                                           | Roque et al. (229)       |
|                                      |                                                              | CD4/CD8 ratio, thymocytes, cortexosterone |                                                                                       | Lubach Coe and Ershler (230) |
|                                      |                                                              | CD8/CD4 cell ratio, natural killer cells, lymphocytes (monkeys) |                                                                                       |                          |
|                                      | Cardio/respiratory control                                  | Synaptic pruning via microglia      | Medulla, Nucleus tractus solitarius, dorsal motor nucleus of vagus                        | Baldy et al. (168)       |
|                                      | CO₂ sensitivity: respiratory response to 6% CO₂ inhalation   | N/A                                 |                                                                                           | Luchetti et al. (164), Cittaro et al. (163), Giannese et al. (166), Battaglia et al. (126), D’Amato et al. (65), Giannese et al. (166) |
|                                      | Early life stressor: repeated cross fostering                | N/A                                 | Peritoneal macrophages                                                                   | Bakker et al. (231), Bakker et al. (232) |
|                                      | CO₂ sensitivity: respiratory response to 5% CO₂ inhalation   | Neonatal dexamethasone treatment increases susceptibility to experimental autoimmune encephalomyelitis in adult rats cortexosterone, TNFα, IL-1β release Changes peripheral T cell Vbeta repertoire changes in microbiota |                                                                                       | Daft et al. (233)        |

(Continued)
| Model                                      | PD-relevant phenotype and effect                                | Potential immune effectors                                               | Brain region(s) implicated            | References                  |
|-------------------------------------------|----------------------------------------------------------------|-------------------------------------------------------------------------|---------------------------------------|-----------------------------|
| Anxiety-relevant behaviors in males       |                                                                  | IL-1β (Astrocytes)                                                      | Hippocampus                          | Bartolomucci et al. (234)  |
| Fear conditioning (freezing)              |                                                                  | IL-1β, IL-18, IL-6, IL-10, monocyte chemotactic protein (MCP-1), DAMPs (uric acid and Hsp72) | Plasma                                | Jones et al. (208), Jones et al. (210), Jones et al. (210) |
| Stress-enhanced fear learning (SEFL)      | N/A                                                             | IL-1β, IL-6, IL-10, monocyte chemotactic protein (MCP-1), DAMPs (uric acid and Hsp72) | Plasma, Periphery                     | Maslanik et al. (235)    |
| Inescapable shocks                        | Fear memory                                                     | IL-1β, IL-6, monocytes, macrophages, IL-1β                               | Spleen, whole brain                  | Lisboa et al. (182)       |
| Predator stress                           | Fear conditioning acquisition (freezing), 2-way Avoidance/Escape (active responding, escape failures), motor activity, fatigue | IL-1β, IL-1R1, TNFα, IL-6                                               | Brain                                | Wohleb et al. (184)      |
| Social defeat/chronic social stress       | Anxiety-relevant behavior (Open field test, elevated plus maze) | IL-1β, IL-6, IL-10, monocytes, macrophages, IL-1β                         | Spleen, whole brain                  | Lisboa et al. (182)       |
| Social defeat/chronic social stress restraint stress | Social exploration                                             | IL-1R1                                                                 | Hippocampus                          | DiSabato et al. (185)    |
| Inescapable shocks                        | Anxiety-relevant (Open field test)                              | IL-1β, monocytes                                                        | Brain                                | Wohleb et al. (187)      |
| Predator stress                           | Anxiety-relevant (light-dark preference)                        | Macrophages, IL-1b, IL-6, TNFα                                         | Brain                                | Wohleb et al. (187)      |
| Social defeat/chronic social stress       | Monocyte-derived microRNA106b~25                                | IL-6                                                                    | periphery                            | Hodes et al. (189)       |
| Social interaction                        | Dihydrocaffeic acid (DHCA) and malvidin-3′-O-glucoside (Mal-gluc), IL-6 | IL-6                                                                    | Nucleus accumbens                    | Menard et al. (191)      |
| Bradypnea                                  |                                                                  | IL-6                                                                    | Dorsal medial hypothalamus, nucleus of the solitary tract | Brouillard et al. (194) |

underlying PD to simulate panic-relevant behaviors and physiology. To date there have been somewhat limited investigations into the role of immune dysregulation in mediating PD-relevant behaviors and physiological outcomes in CO₂ inhalation models. However, support for immune dysregulation in these models is growing. Our lab cloned acid-sensing G protein coupled receptor, T-cell death associated gene-8 (TDAG8) in rodent brain (135), and reported TDAG8 expression on microglia, innate immune cells of the CNS (94), that are recruited in physiological responses to homeostatic fluctuations (136–140). On sensing subtle imbalance in ionic homeostasis, microglia transform rapidly from a resting to an activated state in accordance with their role in maintenance of the CNS microenvironment. Interestingly, TDAG8-expressing microglia were enriched within the sensory circumventricular organs (CVOs) (94). Sensory CVOs such as the subfornical organ (SFO) are integrative sites that lack a blood-brain barrier and have access to systemic and CNS compartments for maintenance of homeostasis (141). Importantly, the SFO has been identified as a site where interoceptive stimuli can be sensed and relayed to panic-generating CNS areas, and has been implicated in regulating panic-relevant responses to other panicogens such as intravenous lactate (142–144). More directly, our data showed targeted infusion of acidified artificial cerebrospinal fluid (aCSF; a homeostatic stress) into the SFO triggers fear-relevant behaviors like freezing; an effect which is dependent on TDAG8 (145). Our data further revealed the necessity of microglial acid-sensor TDAG8 to orchestrate CO₂-evoked behavioral (freezing) and cardiovascular responses relevant to panic via microglial activation, IL-1β signaling, and
SFO neuronal firing (94). Thus, the SFO likely represents a primary locus for detecting interoceptive triggers in “body-to-brain” transmission of panic.

Recruitment of SFO immunomodulatory mechanisms in panic-relevant outcomes is novel, although not surprising, as the SFO is also known to drive immune responses and sickness behaviors, particularly fever, in response to infection (141, 146–148). The SFO also regulates blood pressure (149) as well as respiration (150), and previous studies reported IL-1β-IL-1R signaling mediated cardiovascular activation via the SFO (151). More recent observations from our lab show significant attenuation of CO₂-evoked freezing following SFO-targeted infusion of the IL-1 receptor antagonist, IL-1RA (152), suggesting a primary role of SFO IL-1R1 signaling in CO₂-associated fear behaviors. Notably, the IL-1R1 receptor is localized on endothelial cells within the SFO (152, 153) and is required for CO₂-evoked activation of SFO neurons (94). The SFO could be mediating these effects though its direct projections to brain areas mediating defensive behaviors and physiological responses relevant to panic such as the hypothalamus, prefrontal cortex, BNST, and periaqueductal gray (154, 155). Collectively, our data highlight a contributory role of neuroimmune signaling and specialized sites such as the SFO in regulation of panic-relevant behavior and physiology.

2) Early Life Stress- CO₂ respiratory dysfunction paradigm

Strong evidence supports significant variance and individual differences in responding to CO₂ inhalation (38, 47, 156). People with panic lie at one extreme of the sensitivity distribution, showing paroxysmal hyperventilation and panic when they undergo CO₂ challenges (38, 52, 58, 61, 157). Modeling CO₂ sensitivity in rodents as a proxy for human panic has unique strategic advantages such as an opportunity to dissect mechanistic contributions. Studies performed by Battaglia and coworkers have highlighted gene x environment interactions in mediating increased CO₂ sensitivity [reviewed in (158–160)]. Chronic stress in the form of early life adversity for example childhood parental loss, contributes to these relationships (158, 161), and stressful life events occurring in childhood-adolescence heighten young adults’ CO₂ sensitivity (162).

Transitionally relevant paradigms such as neonatal maternal separation (NMS) and repeated cross fostering (RCF) model have effectively simulated the effects of early life stress on CO₂ sensitivity and provided mechanistic insights [reviewed in (158, 160)]. Heightened ventilatory response to CO₂ inhalation is observed in adult animals with a history of NMS or RCF as neonates (65, 126, 163–167), that may be regulated by gene x environment factors and epigenetic alterations in gene methylation patterns (163, 166). Interestingly, significant increase in microglial density and reduced arborization was observed within the nucleus of the solitary tract (cNTS) and the dorsal motor nucleus of the vagus (DMNV), two key areas regulating breathing (168) suggesting that NMS may compromise microglial ability to perform optimal synaptic pruning that could lead to aberrant respiratory control. In a more recent study (169), the group reported a significant effect of ovarian hormones on microglial activation within in CO₂/H⁺ sensing brain stem areas, suggesting that hormonal fluctuations may influence anomalies of respiratory control via neuroimmune mechanisms. Given that effects of early life stress on immune signaling, neuroimmune physiology and function are well established [for review see (110, 170–172)], more investigation is warranted on the delineating the links between ELS-immune signaling and panic-relevant physiology.

3) Chronic Social Defeat paradigms - body to brain immune signaling in anxiety and fear

As described in preceding sections, exposure to exoerceptive stressors and aversive contexts can facilitate the recurrence of panic attacks. Furthermore, dysregulation of stress response systems has been implicated in PD, particularly the sympathetic nervous system that regulates the immune system via innervation of the spleen and lymphoid organs [Webster Marketon and Glaser (173); Dantzer (174)]. A primary role of chronic stress mediated immune dysfunction and CNS remodeling has been recognized in the genesis of psychiatric illnesses, including mood and anxiety disorders [reviewed in (24, 71, 72, 175)]. Recurrent or chronic stress engages intrinsic neuronal pathways that lead to physiological effects, such as neuroendocrine and sympathetic activation (176, 177). These systemic responses to stress further promote the release and trafficking of myeloid cells with enhanced inflammatory potential into various organs, including the brain (178, 179). Preclinical rodent models of stress-induced behavior and physiology can provide important information on brain-to-body as well as body-to-brain communication mechanisms. In this regard, psychosocial stress paradigms, particularly repeated social defeat (RSD) stress exposure [reviewed in (114, 179–181)] have yielded important mechanistic information on body-brain neuroimmune crosstalk in regulating fear extinction (182), anxiety and social avoidance behaviors [reviewed in (179)] that are relevant to persistent fear, anxiety and comorbid depression observed in PD. Coordinated events including activation of brain threat appraisal sites, microglial activation and peripheral immune signaling is reported to orchestrate RSD-mediated behavioral deficits. Exposure to RSD leads to increased sympathetic activation promoting elevated noradrenergic signaling in the periphery and increased production and release of glucocorticoid-insensitive monocytes into the circulation from the bone marrow and spleen [reviewed in (114, 183)]. Pharmacological and genetic intervention strategies using adrenergic receptor antagonists, microglial activation blockers, cell specific IL-1R transgenic mice highlight a key role of sympathetic activation, microglia-mediated trafficking of reactive IL-1β- releasing monocytes to the brain,
and the recruitment of endothelial and neuronal IL-1R1 in promoting RDS induced expression of anxiety-associated behaviors and reduced social interaction (184–187). Although IL-1-mediated mechanisms appear to be important in the RDS model, it would be important to note that other cytokine mediators, like interleukin-6 have also been implicated in social defeat stress-induced blood brain barrier alterations and impaired social interaction behavior (188–191). In addition to adverse behavioral effects, social defeat exposure has long term effects on cardiovascular responses (192, 193) and aberrant respiratory patterns (194) that are of relevance to PD. Immune dysfunction and inflammatory mechanisms contribute to increased cardiovascular and autonomic activation in stressed mice (195, 196).

In summary, previous work has highlighted the relevance of social defeat stress paradigms to anxiety and depression physiology. However, the observed crosstalk of sympathetic activation, peripheral immune signaling and brain networks regulating behavior and physiological responses in this model may also relate to panic physiology.

4) Fear Conditioning paradigms

Pavlovian fear conditioning has been central to understanding the etiology of anxiety disorders such as PD [reviewed in (197)]. The clinical relevance of fear conditioning to PD is based on conditioned fear responses to panic-evoking stimuli and contexts, as well as generalized fear to resembling cues. Conditioning processes contribute by conferring fear and anxiogenic valence to these conditioning triggers that enable the maintenance of the disorder well after the termination of the unconditioned stimulus (i.e., the panic attack). The measurement of Pavlovian fear conditioning and extinction in rodents offers a relatively simple paradigm that is translatable as an approach to study biological underpinnings of fear-related disorders (198–201). While most rodent studies highlight the applicability of their findings to PTSD, they are also pertinent to PD symptomology. In this section we discuss evidence supporting a role of several immune factors and neuroimmune signaling in regulating conditioned fear associated behaviors. We discuss selected fear conditioning studies in this section excluding models of neurodegeneration, addiction or severe inflammatory insults.

A role of IL-6 in the maintenance of fear memory was reported using auditory cue fear conditioning, an effects dependent on fear extinction, suggesting that IL-6 and other IL-6 related pro-inflammatory cytokines may contribute to the persistence of fear memory (76). Another study reported impairment of acquisition and extinction of fear following intra-amygdala injection of IL-6 (202). Fear regulatory effects of other cytokines and T cells have also been investigated. Levels of TNF-α were increased in microglia from mice representing extinction (203), suggesting that sustained fear is facilitated by microglial TNF-α signaling. A role of NLPR3 inflammasome activation and IL-1β has also been reported in the regulation of fear memory (204). Genetic knockout and pharmaceutical inhibition of the NLPR3 inflammasome enhanced the extinction of contextual fear memory. IL-1β administration inhibited extinction, while, IL-1RA (IL-1R antagonist) facilitated extinction. In addition to cytokines associated with innate immune signaling, the role of CD4(+) T cells in promoting fear responses by enhancing learning and memory processes has been reported (205). Lymphocyte deficient Rag2(-/-) mice showed attenuated fear responses in a cued fear conditioning paradigm compared to wild-type mice and reconstitution with CD4(+) T cells promoted fear learning and memory.

Stress-enhanced fear learning (SEFL), which encompasses both trauma and memory components in rodents, has emerged as a valuable preclinical model for PTSD [reviewed in (206)], and may be pertinent to the conditioned aspects of PD physiology. SEFL simulates the impact of traumatic stress in the form of several footshocks on subsequent fear conditioning to a single shock delivered in a novel context (207). Maladaptive behavioral outcomes following traumatic footshocks in the SEFL paradigm have been associated with immune dysregulation, specifically, a central role of hippocampal IL-1β has been reported (208–210). Exposure to footshocks induced a time-dependent increase in IL-1β expression within the hippocampal dentate gyrus, and IL-1RA treatment prevented the development of SEFL (208). Interestingly, hippocampal astrocytes were reported to be the source of IL-1β (209). To confirm a key role of astrocyte signaling in SEFL, the same group investigated the effects of glial-expressing DREADD construct [AAV8-GFAP-hM4Di(Gi)-mCherry] delivered in the dorsal hippocampus (210). Inhibition of astroglial G₁ activation was sufficient to attenuate SEFL, suggesting that IL-1β signaling involves glial-neuronal interactions in stress potentiation of fear.

Collective evidence from these studies suggests that immune signaling has regulatory effects on fear learning and memory processes and that dysregulated immune status in PD could promote sustained and generalized fear.

Potential immune links in panic disorder: Takeaways and future directions

Mounting evidence supports a role for neuroinflammation in PD, however, questions remain about the specific mechanisms and effectors contributing to pathology. Clinical observations suggest that PD associates with heightened peripheral inflammation at baseline. Patients with PD also present with hyperactive homeostatic stress responsivity, particularly
in response to acid-base imbalance, which associates with dysregulated immune responses to stress. Our working model (see Figure 2) proposes a complex interplay between peripheral and central inflammatory mechanisms, and a hyperactive response system to homeostatic stress. While it is currently unclear if hyperactive homeostatic stress responsivity leads
to dysregulated inflammatory signaling or if a heightened inflammatory state increases sensitivity to homeostatic stressors, it is likely the relationship is bidirectional with either facilitating the other. The exacerbation of sensitivity to homeostatic stressors like acidosis and peripheral inflammation then promotes the behavioral, emotional and physiological symptoms of panic attacks through neuroinflammatory mechanisms and dysregulated neuroimmune signaling within the brain and ultimately, leads to the development of PD.

An important question going forward involves the relationship between peripheral and central inflammation, and how inflammation reaches the brain to ultimately drive panic symptomology. Though it is unclear how inflammation could reach the brain in PD, homeostatic stressors like acidosis could lead to altered neuroimmune signaling within the brain through a variety of mechanisms (Figure 2A). In the periphery, acidosis may activate acid-sensing receptors on peripheral macrophages and lead to release of cytokines that either activate cytokine receptors on endothelial cells or cross the BBB to activate receptors directly within the brain. Alternatively, peripheral acidosis could acidify the brain via protons (H+) that cross the BBB and activate acid-sensing receptors on microglia. Another possibility is that acidosis occurs directly within the brain activating acid-sensing receptors on microglia resulting in cytokine release and activation of cytokine receptors on endothelial cells or directly on neurons or other cell types. The BBB generally protects against infiltration from peripheral immune cells, however mounting evidence suggests mood, anxiety and stress-associated psychiatric disorders like PTSD and depression associate with changes in BBB permeability (191, 211–213). In PD, it is possible that prior trauma, chronic stress or comorbidities such as PTSD or depression which associate with changes in BBB permeability could cause peripheral macrophages to penetrate the brain, which could then be activated by subsequent acidosis. It is also possible that repeated activation of peripheral macrophages could alter the BBB and lead to changes in how peripheral macrophages interact or engage with the peripheral-endothelial-BBB interphase. Future studies are needed to identify which, if any, of these mechanisms contribute to neuroinflammation in PD and determine whether targeting these mechanisms could improve treatment outcomes.

Future studies are also needed to identify how inflammatory signaling is translated into neuronal signaling within the brain to ultimately regulate panic symptomology. The conversion of immune signaling into neuronal signaling could originate either in the periphery or directly in brain (Figure 2B). In the periphery, neuro-immune signaling could result in vagal stimulation that terminates in the nucleus tractus solitarius (NTS) and mediates cardiovascular and respiratory responses (214). There could also be direct humoral signaling within circumventricular organs the subfornical organ (SFO) or area postrema (AP). These areas are known to project directly to fear, respiratory and cardiovascular regulatory areas throughout the brain (147). Alternatively, inflammation could occur directly in the brain in response to stress (interoceptive/homeostatic or exteroceptive), trauma, or panic context re-exposure. Many studies have shown increased inflammation in fear-associated regions prefrontal cortex (PFC), hippocampus (HPC), amygdala (AMY) or the NTS (75, 83, 204, 208, 209, 215–217). Inflammation in these areas could affect neuronal activity and drive the emotional, behavioral and physiological responses associated with PD pathology.

Another consideration is the level of inflammation associated with pathology. Historically, most studies on the role of innate immune cells within the brain have focused on the effects of high levels of neuroinflammation more typically associated with PD than increased inflammatory signaling within the brain. Even mild perturbations in the immune milieu can have neuromodulatory effects. Innate immune cells contribute to homeostatic maintenance of the CNS and dysregulation of this functionality may lead to pathology (140). For example, microglia have an important role in the synaptic pruning (72). Dysregulated synaptic pruning could have lasting effects on neurotransmission and mounting evidence suggests an association of dysregulated synaptic pruning with psychiatric disorders like depression or autism. There is also an association between inflammation and increased oxidative stress in psychopathology which could exacerbate cell damage, alter cell signaling within the brain and result in behavioral changes (218–221). Additionally, at lower concentrations cytokines may act as neuromodulators within the brain, changing excitability and having more mild effects on cognition/memory/decision making rather than inducing robust sickness behaviors at higher concentrations (70). In the case of PD, a lack of evidence for drastic effects on immune function might be due to relatively mild changes on the innate immune system, resulting in changes to homeostatic maintenance or monocyte trafficking to endothelial cells at the BBB rather than increased cell death or infiltration of peripheral monocytes/T cells as a result of BBB degradation.

Lastly, the high level of co-morbidity between PD and inflammatory diseases such as multiple sclerosis (222), lupus (89, 223), asthma (30, 224), and irritable bowel syndrome (225), as well as other psychiatric disorders associated with inflammation like depression (6, 14, 226), PTSD (6, 227) and substance use disorders (6, 14) supports a role for dysregulated immune signaling in PD risk and pathology. However, the mechanisms driving high comorbidity are unclear and particularly complex as either PD or the inflammatory disorder may pre-date the other. For example, initial presentation with an inflammation-associated disorder could drive changes in homeostatic sensitivity and lead to increased risk for developing panic, innate sensitivity to homeostatic stressors could lead to
development of a heightened inflammatory state and increase risk for developing inflammation-associated co-morbidities, or the same underlying inflammatory pathways may drive pathology in PD and commonly co-morbid inflammatory disorders and be dysregulated in affected individuals. Future studies are needed to determine the relationship between these disorders and the mechanisms through which one may lead to the other.

Overall, strong evidence supports the hypothesis that dysregulated body to brain signaling is central to the development of PD. Emerging clinical and preclinical evidence points to a strong role for dysregulated immune signaling in driving the dysfunctional body to brain signaling underlying spontaneous and cued panic attacks. However, further studies are needed to better understand neuroinflammatory mechanisms in PD.

Author contributions

KM and RS conceived of the project, wrote and edited the manuscript, and provided funding. Both authors contributed to the article and approved the submitted version.

Funding

This work was supported by R01MH093362 and R21MH083213 and VA Merit Grant I01-BX001075 to RS, as well as postdoctoral training award F32MH117913 and Pathway to Independence award K99AA029168 to KM.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Nord CL, Garfinkel SN. Interceptive pathways to understand and treat mental health conditions. Trends Cogn Sci. (2022) 26:499–513. doi: 10.1016/j.tics.2022.03.004
2. James W. What is an emotion? Mind. (1884) 9:188–205. doi: 10.1093/mind/os-IX.34.188
3. Damasio A, Carvalho GB. The nature of feelings: evolutionary and neurobiological origins. Nat Rev Neurosci. (2013) 14:143–52. doi: 10.1038/nrn3403
4. Khalsa SS, Adolphs R, Cameron OG, Critchley HD, Davenport PW, Feinstein JS, et al. Interception and mental health: a roadmap. Biol Psychiatry Cogn Neurosci Neuroimaging. (2018) 3:501–13. doi: 10.1016/j.bpsc.2018.04.007
5. Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE. The epidemiology of panic attacks, panic disorder, and agoraphobia in the national comorbidity survey replication. Arch Gen Psychiatry. (2006) 63:415–24. doi: 10.1001/archpsyc.63.4.415
6. de Jonge P, Roest AM, Lim CCW, Florescu SE, Bromet EJ, Stein DJ, et al. Cross-national epidemiology of panic disorder and panic attacks in the world mental health surveys. Depress Anxiety. (2016) 33:1155–77. doi: 10.1002/da.22572
7. Gros DF, Frueh BC, Magruder KM. Prevalence and features of panic disorder and comparison to posttraumatic stress disorder in VA primary care. Gen Hosp Psychiatry. (2011) 33:482–8. doi: 10.1016/j.genhosppsych.2011.06.005
8. Beesdo K, Pine DS, Lieb R, Wittchen HU. Incidence and risk prediction of anxiety disorder. Arch Gen Psychiatry. (2010) 67:47–57. doi: 10.1001/archgenpsychiatry.2009.177
9. Gadermann AM, Alonso J, Gratch J, de Miranda R, Artiga S, Chouinard S, et al. Cross-national burden of mental disorders in the World Mental Health Surveys: the world mental health surveys version 2.0 (WMH 2.0). Epidemiol Psicopathol Ment Health. (2010) 19:75–85. doi: 10.1007/s10603-010-9180-2
10. Birmaher B, Williamson D, Pliszka SR, Williamson DE, Williamson DA, Keshavan M, et al. National Institute of Mental Health (NIMH)-supported research on childhood and adolescent depression: scientific and practical perspectives. Depress Anxiety. (2004) 19:241–7. doi: 10.1002/da.10639
11. Klein DF. False suffocation alarms, spontaneous panics, and related conditions. An integrative hypothesis. Arch Gen Psychiatry. (1993) 50:306–17. doi: 10.1001/archpsyc.1993.01820160076009
12. Smoller JW, Tsuang MT. Panic and phobic anxiety: defining phenotypes for genetic studies. Am J Psychiatry. (1999) 156:1152–62. doi: 10.1176/ajp.156.9.1152
13. Eaton WW, Kessler RC, Wittchen HU, Magee WJ. Panic and panic disorder in the United States. Am J Psychiatry. (1994) 151:413–20. doi: 10.1176/appi.ajp.151.3.413
14. Craske MG, Kircanski K, Epstein A, Wittchen H-UU, Pine DS, Lewis-Fernández R, et al. Panic disorder: a review of DSM-IV panic disorder and proposals for DSM-V. Depress Anxiety. (2010) 27:95–112. doi: 10.1002/da.20654
15. Roy-Byrne PP, Craske MG, Stein MB. Panic disorder. Lancet. (2006) 368:1023–32. doi: 10.1016/S0140-6736(06)6918-X
16. Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. J Am Med Assoc. (2000) 283:2529–36. doi: 10.1001/jama.283.19.2529
17. Yonkers KA, Bruce SE, Dyck IR, Keller MB. Chronicity, relapse, and illness—Course of panic disorder, social phobia, and generalized anxiety disorder: findings in men and women from 8 years of follow-up. Depress Anxiety. (2003) 17:173–9. doi: 10.1002/da.10106
18. Vollmer LL, Strawn JR, Sah R. Acid–base dysregulation and chemosensory mechanisms in panic disorder: a translational update. Transt Psychiatry. (2015) 5:672–572. doi: 10.1038/tpp.2015.67
19. Wemmie JA. Neurobiology of panic and pH chemosensory in the brain. Dialogues Clin Neurosci. (2011) 13:475–83. doi: 10.31887/DCNS.11.13.4/19wemmie
20. Johnson PL, Federici LM, Shekhar A. Etiology, triggers and neurochemical circuits associated with unexpected, expected, and laboratory-induced panic attacks. Neuropsychobiology. (2014) 69:429–54. doi: 10.1007/s00137-014-07027
by cardiac cycle, interoceptive accuracy and personality. NeuroPsychoPharmacology (2017) 42:62–80. doi: 10.1038/npp.2016.90

52. Tarter RE, Switala J, Carra J, Edwards KL. Inflammatory bowel disease: psychiatric status of patients before and after disease onset. J Int Med Res. (1997) 17:173–81. doi: 10.1177/030881469701700185

53. Trkulja V, Baric H. Current research on complementary and alternative medicine (CAM) in the treatment of major depressive disorder: an evidence-based approach. Adv Exp Med Biol. (2011) 695:375–472. doi: 10.1007/978-1-4419-6640-4_20

54. Boustou ME, Mineka S, Barlow DH. A modern learning theory perspective on the etiology of panic disorder. Psychol Rel. (2001) 108:4–32. doi: 10.1176/appi.ps.1033-295X.108.1.4

55. Gorman JM, Kent JM, Sullivan GM, Coplan JD. Neuroanatomical hypothesis of panic disorder, revised. Am J Respir Crit Care Med. (2000) 162:13–48. doi: 10.1164/ajrccm.162.1.9905001

56. Quagliato LA, Freire RC, Nardi AE. The role of acid-sensitive ion channels in panic disorder: a systematic review of animal studies and meta-analysis of human subjects. Eur Neuropsychopharmacol. (2015) 25:1230–41. doi: 10.1016/j.euroneuro.2015.04.001

57. Papp LA, Martin J, Klein DF, Coplan JD, Norman RG, Cole R, et al. Respiratory psychophysiology of panic disorder: three respiratory challenges in 98 subjects. Am J Psychiatry. (1997) 154:1557–65.

58. Sanderson WC, Weterl S. Five percent carbon dioxide challenge: valid analogue and marker of panic disorder? Biol Psychiatry. (1990) 27:899–901. doi: 10.1016/0006-3223(90)90300-X

59. Gorman JM, Browne ST, Papp LA, Martin J, Welkowitz L, Coplan JD, et al. Effect of antipanic treatment on response to carbon dioxide. Biol Psychiatry. (2004) 55:288–891. doi: 10.1016/j.biopsych.2005.01.015

60. Rappaport LM, Sheerin C, Savage JE, Hettema JM, Roberson-Nay RJ. Clinical characteristics of latent classes of CO2 hypersensitivity in adolescents and young adults. Behav Res Ther. (2017) 93:95–103. doi: 10.1016/j.bret.2017.03.015

61. Fishman SM, Carr DB, Beckett A, Rosenbaum F. Hypercapnic ventilatory response in patients with panic disorder before and after alprazolam treatment and in pre- and postmenstrual women. J Psychiatr Res. (1994) 28:165–70. doi: 10.1016/0022-3956(94)90027-2

62. Maddock RJ. The lactic acid response to alkalosis in panic disorder? An integrative review. J Neuropsychiatry Clin Neurosci. (2005) 13:22–34. doi: 10.1176/jnp.13.1.22

63. Strackx E, et al. The brain acid-base homeostasis and serotonin: a perspective. Acta Psychiatr Scand Suppl. (2015) 138:161228803530745

64. Coryell W, Rickels H. Effects of eszopram on anxiety and respiratory responses to carbon dioxide inhalation in subjects at high risk for panic disorder: a placebo-controlled, crossover study. J Clin Psychopharmacol. (1999) 19:147–54. doi: 10.1097/00004712-199902000-00029

65. D'Amato FR, Zanettini C, Lampis V, Coccurello R, Pascucci T, Ventura R, et al. Sensitivity to carbon dioxide challenge test in panic disorder: a systematic review of preclinical and clinical research. Rev Bras Pneumol. (2013) 39:118–31. doi: 10.1590/1806-3415-2012-1045

66. Harrison WM, Sandberg D, Gorman JM, Fyer M, Nee J, Uy J, et al. Provocation of panic with carbon dioxide inhalation in patients with premenstrual dysphoria. Psychiatry Res. (1989) 27:183–92. doi: 10.1016/0165-1781(89)90133-9

67. Bailey JE, Argyropoulos SV, Kendrick AH, Nutt DJ. Behavioral and cardiovascular effects of 7.5% CO2 in human volunteers. Depress Anxiety. (2005) 21:18–25. doi: 10.1002/da.20048

68. Fyer MR, Uy J, Martinez J, Goertz R, Klein DF, Fyer A, et al. CO2 challenge of patients with panic disorder. Am J Psychiatry. (1987) 144:1080–2. doi: 10.1176/ajp.144.8.1080

69. Leibold NK, van den Hove DL, Vachbauer W, Buchanan GF, Goossens L, Lange I, et al. CO2 exposure as translational cross-species experimental model for panic. Transl Psychiatry. (2016) 6:e885. doi: 10.1038/tp.2016.162

70. Coryell W, Rickels H. Effects of eszopram on anxiety and respiratory responses to carbon dioxide inhalation in subjects at high risk for panic disorder: a placebo-controlled, crossover study. J Clin Psychopharmacol. (1999) 19:147–54. doi: 10.1097/00004712-199902000-00029

71. Mehler M, Muhr M, Noack S, Leichenring J, Wiedemann K, Yassouridis A. Effects of 35% carbon dioxide (CO2) inhalation in patients with post-traumatic stress disorder (PTSD): a double-blind, randomized, placebo-controlled, cross-over trial. J Psychiatr Res. (2018) 96:260–4. doi: 10.1016/j.jpsychires.2017.10.019

72. Perna G, Ho HP, Annerbrink K, Thylefors J, Eriksson E. Respiratory responses to intravenous infusion of sodium lactate in male and female wistar rats. Neuropsychopharmacology. (2015) 40:55–68. doi: 10.1038/npp.2014.90
sensitivity induced by gene-by-environment interplay. PLoS One. (2011) 6:2–12. doi: 10.1371/journal.pone.0018637
66. Bandelow B, Spah C, Alvarez Tschauer G, Broocks A, Hajek G, Ruther E. Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with panic disorder. Compr Psychiatry. (2002) 43:269–78. doi: 10.1053/cc.2002.33492
67. Lissek S, Rabin S, Heller RE, Lukenbaugh D, Geraci M, Pine DS, et al. Overgeneralization of conditioned fear as a pathogenic marker of panic disorder. Am J Psychiatry. (2010) 167:47–55. doi: 10.1176/appi.ajp.2009.09030410
68. Holtz K, Pané-Farré CA, Wendi I, Lotze M, Hamm AO. Brain activation during anticipation of interoceptive threat. Neuroimage. (2012) 61:857–65. doi: 10.1016/j.neuroimage.2012.03.019
69. Wu Y, Dussing-Olensen L, MacVicar RA, Stevens B. Microglia: dynamic mediators of synaptic development and plasticity. Trends Immunol. (2015) 36:805–13. doi: 10.1016/j.ti.2015.08.008
70. Kronolf Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry. (2000) 157:683–94. doi: 10.1176/appi.ajp.157.5.683
71. Dwyer JR, Ross DA, Schafer DP, LehrmanEK, Stevens B, Wohleb ES, et al. Modern microglia: novel targets in psychiatric neuroscience. Biol Psychiatry. (2016) 80:87–9. doi: 10.1016/j.biopsych.2016.08.006
72. Bollinger JL, Wohleb ES. The formative role of microglia in stress-induced synaptic deficits and associated behavioral consequences. Neurosci Lett. (2019) 711:134369. doi: 10.1016/j.neulet.2019.134369
73. Tsyglykova M, McDaniel D, Hodes GE. Immune mechanisms of stress susceptibility and resilience: lessons from animal models. Front Neuroendocrinol. (2019) 54:e100771. doi: 10.1016/j.yfrne.2019.100771
74. McKimb DB, Patterson JM, Wohleb ES, Jarrett BL, Reader BE, Godbout JP, et al. Sympathetic release of splenic monocytes promotes recurring anxiety following repeated social defeat. Biol Psychiatry. (2016) 79:803–13. doi: 10.1016/j.biopsych.2015.07.016
75. Michopoulos V, Powers A, Gillespie CF, Resler KJ, Jovanovic T. Inflammation in fear-and anxiety-based disorders: PTSD, GAD, and beyond. Neuropsychopharmacology. (2017) 42:254–70. doi: 10.1038/npp.2016.146
76. Young MB, Howell LL, Hopkins L, Moshefgh C, Yu Z, Clibbon L, et al. A peripheral immune response to remembering trauma contributes to the maintenance of fear memory in mice. Psychoneuroendocrinology. (2018) 94:143–51. doi: 10.1016/j.psyneuen.2018.05.012
77. Deslauriers J, Powell SB, Rubrugh VB. Immune signaling mechanisms of PTSD risk and symptom development: insights from animal models. Curr Opin Behav Sci. (2017) 14:123–32. doi: 10.1016/j.cobeha.2017.01.005
78. Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry. (2001) 158:1568–78. doi: 10.1176/appi.ajp.158.10.1568
79. Kim HJ, YK Kim. The G allele in IL–10:1082 G/A may have a role in lowering the susceptibility to panic disorder in female patients. Acta Neuro Psychiatr Jpn. (2016) 28:357–61. doi: 10.15834/jn.2016.25
80. Smith EM, Cadet P, Stefano GB, Opp MR, Hughes TK. IL-10 as a mediator in translational approach evidenced by epidemiological and clinical studies and a murine model. Neuropsychopharmacology. (2018) 43:342–53. doi: 10.1038/npp.2017.102
81. prelog M, Hilligardt D, Schmidt CA, Przybylski GK, Leierer J, Almanzar G, et al. Cytokine expression profiling of CCK-4-induced panic in healthy subjects. Am J Med Genet Part B Neuropsychiatr Genet. (2010) 153:269–74.
82. Hoge EA, Brandstetter K, Mosher S, Pollack MH, Wong KK, Simon NM. Broad spectrum of cytokine abnormalities in panic disorder and posttraumatic stress disorder. Depress Anxiety. (2009) 26:47–55. doi: 10.1002(da).20054
83. Quagliauto LA, Nardi AE. Cytokine alterations in panic disorder: a systematic review. J Affect Disord. (2010) 122:9. doi: 10.1016/j.jad.2011.11.094
84. Zou Z, Zhou B, Huang Y, Wang J, Min W, Li T. Differences in cytokines between patients with generalised anxiety disorder and panic disorder. J Psychosom Res. (2020) 133:109975. doi: 10.1016/j.jpsychores.2020.109975
85. Van Duinen MA, Schruers KRJ, Kenis GRL, Wauters A, Delanghe J, Giezell, ET, et al. Effects of experimental panic on neuroimmunological functioning. J Psychosom Res. (2008) 64:305–10. doi: 10.1016/j.jpsychores.2007.10.004
86. Tükel R, Arslan BA, Ertekin BA, Ertekin E, Oflar S, Ergun A, et al. Decreased IFN-γ and IL-12 levels in panic disorder. J Psychosom Res. (2012) 73:63–7. doi: 10.1016/j.jpsychores.2012.04.012
87. Brambilla F, Bello Gi, Perna Gi, Bertani A, Panerai A, Sacerdote P. Plasma interleukin-1 beta concentrations in panic disorder. Psychiatria (1994) 54:135–42. doi: 10.1006/psyc.1994.0002-7
88. Dantzer R, O Connor JC, Freund GF, Johnson RW, Kelley KW. From innate immunity to brain. Nat Rev Neurosci. (2001) 9:46–56. doi: 10.1038/nnrev2297
89. Weiss G, Murr C, Zoller H, Haun M, Widner B, Ludescher C, et al. Modulation of neopterin formation and tryptophan degradation by Th1 and Th2-derived cytokines in human monocyctic cells. Clin Exp Immunol. (1999) 116:435–40. doi: 10.1111/j.1365-2249.1999.00910.x
90. Traks T, Koido K, Baltsot R, Eller T, Koks S, Maron E, et al. Polymorphisms of IKBKE gene are associated with major depressive disorder and panic disorder. Brain Behav. (2015) 5:e00314. doi: 10.1002/brb3.314
91. Sankar S, Chan H, Romanow WJ, Li J, Bates RJ. IKK-i signals through IRF3 and NFkappaB to mediate the production of inflammatory cytokines. Cell Signal. (2006) 18:9982–93. doi: 10.1016/j.cellsig.2005.08.006
92. Foldager L, Ko O, Steffensen R, Thiel S, Kristensen AS, Christian J, et al. Bipolar and panic disorder may be associated with hereditary defects in the immune system. J Affect Disord. (2014) 164:148–54. doi: 10.1016/j.jad.2014.04.017
Nettis MA, Pariante CM, Mondelli V. Early-life adversity, systemic inflammation and comorbid physical and psychiatric illnesses of adult life. Curr Top Behav Neurosci. (2020) 24:207–25. doi: 10.1007/978-3-030-02006-0_9

Abelson JL, Khan S, Libezon I, Young EA. HPA axis activity in patients with panic disorder: review and synthesis of four studies. Depress Anxiety. (2007) 24:66–76. doi: 10.1002/da.20220

Moynihan J, Krueszewska B, Madden K, Callahan T. Sympathetic nervous system regulation of immunity. J Neuroimmunol. (2004) 147:87–90. doi: 10.1016/j.jneuroim.2003.10.018

Moynihan JA. Mechanisms of stress-induced modulation of immunity. Brain Behav Immun. (2007) 13:71–116. doi: 10.1016/S0889-1983(00)00060-0

Wohlebe ES, McKim DB, Sheridan JR, Godbout JP. Monocyte trafficking to the brain with stress and inflammation: a novel axis of immune-to-brain communication that influences mood and behavior. Front Neurosci. (2015) 9:447. doi: 10.3389/fnins.2014.00447

Won E, Kim YK. Neuroinflammation-associated alterations of the brain as potential neural biomarkers in anxiety disorders. Int J Mol Sci. (2020) 21:1–19. doi: 10.3390/ijms21181656

Stepone A, Hamer M, Chida Y. The effects of acute psychological stress on circulating inflammatory factors in humans: a review and meta-analysis. Brain Behav Immun. (2007) 21:901–12. doi: 10.1016/j.bbi.2007.03.011

Deinzer R, Granath N, Stuhl H, Twork L, Idle H, Waschul S, et al. Acute stress effects on local IL-1β responses to pathogens in a human in vivo model. Brain Behav Immun. (2010) 24:458–47. doi: 10.1016/j.bbi.2010.11.008

Von Kanel R, Kudelaika BM, Preckel D, Hanebuth D, Fischer JE. Delayed response and lack of habituation in plasma interleukin-6 to acute mental stress in men. Brain Behav Immun. (2006) 20:40–8. doi: 10.1016/j.bbi.2005.03.013

Petrowski K, Wichmann S, Sirschbaum C. Stress-induced pro- and anti-inflammatory cytokine concentrations in panic disorder patients. Psychoneuroendocrinology. (2018) 94:31–7. doi: 10.1016/j.psyneuen.2018.05.005

Grillon C, Ameli R, Goddard A, Woods SW, Davis M. Baseline and fear-potentiated startle in panic disorder patients. Biol Psychiatry. (1994) 35:431–9. doi: 10.1016/0006-3223(94)90040-X

Santos M, D’Amico D, Dierssen M. From neural to genetic substrates of panic disorder: insights from human and mouse studies. Eur J Pharmacol. (2015) 759:127–41. doi: 10.1016/j.ejphar.2015.03.039

Schenberg LC, Schimitel FG, Armini Rde S, BernabÈ CS, Rosa CA, Tufik S. et al. Translational approach to studying panic disorder in rats: hits and misses. Therap Adv Psychopharmacol. (2019) 9:447. doi: 10.1177/2045125318784872

Kinead R, Tenorio L, Drolert G, Bøgntsen J, Gargaglioni L. Respiratory manifestations of panic disorder in animals and humans: a unique opportunity to understand how supramedullary structures regulate breathing. Respir Physiol Neurobiol. (2014) 204:13–3. doi: 10.1016/j.resp.2014.06.013

Moreira FA, Gobira PH, Yáñez-Tapia M, Zangrossi H, Graeff FG. Modeling panic disorder in rodents. Cell Tissue Res. (2013) 354:119–25. doi: 10.1007/s00441-013-1410-1

Tenorio-Lopes L, Fournier S, Henry MS, Bøgntsen J, Kinead R. Disruption of estradiol regulation of orexin neurons: a novel mechanism in excessive angiotensin receptors and panic. Prog Neuropsychopharmacol Biol Psychiatry. (2013) 44:248–56. doi: 10.1016/j.pnpbp.2013.02.014

Kinead R, Bøgntsen J, Allgire E, Shukla S, Jones J, et al. The subformal organ regulates acidosis - evoked fear by engaging microglial acid - sensing ion channels in the basolateral amygdala in panic disorder patients. Prog Neuro-Psychopharmacology Biol Psychiatry. (2019) 81:178–86. doi: 10.1016/j.pnpbp.2019.01.008

Li Q, Barres BA. Microglia and macrophages in brain homeostasis and disease. Nat Rev Neurosci. (2018) 18:225–42. doi: 10.1038/nrn.2017.125

Johnson AK, Gros PM. Sensory circuittry interfering organs and brain homeostatic pathways. FASEB J. (1993) 7:678–86. doi: 10.1096/fasebj.7.8.8500693

Shekhar A, Keim SR. The circumventricular organs form a potential neural pathway for lactate sensitivity: implications for panic disorder. J Neurosci. (1997) 17:9726–35. doi: 10.1523/JNEUROSCI.17-24-09726.1997

Johnson PL, Sadjak TJ, Fitz SD, Hale MW, Lowey CA, Hay-Schmidt A, et al. Angiotensin II’s role in sodium lactate-induced panic-like responses in rats with repeated urocortin 1 injections into the basolateral amygdala. Am J Physiol Regul Integr Comp Physiol. (2004) 286:R405–15. doi: 10.1152/ajpregu.00103.2010

Shekhar A, Sadjak TS, Keim SR, Yoder KK, Sanders SK. Role of the basolateral amygdala in panic disorder. Ann N Y Acad Sci. (1999) 877:747–50. doi: 10.1111/j.1749-6632.1999.tb09315.x

Winter A, McMurray KMJ, Ahlbrand R, Allgire E, Shukla S, Jones J, et al. The subformal organ regulates acidosis – evoked fear by engaging microglial acid – sensor TDA58 and forebrain neurocircuits in male mice. J Neurosci Res. (2020) 200:1732–46. doi: 10.1002/jnr.25059

Cartett T, Lushesi GN, Rothwell NJ. Brain sites of action of endogenous interleukin-1 in the febrile response to localized inflammation in the rat. J. Physiol. (1999) 518:585–94. doi: 10.1113/jphysiol.1999.00585p.x

McKinley MJ, McAlen RM, Davern P, Giles ME, Penschow J, Sunn N, et al. The sensory circuittry interfering organs of the mammalian brain. (Vol. 172). Berlin: Springer; (2003). 184 pp. doi: 10.1007/978-3-642-55532-9

McKinley MJ, Ahlbrand R, Bøgntsen J, Oldfield JB. Interaction of circulating hormones with the brain: the roles of the subformal and the organum vasculosum of the lamina terminalis. Clin Exp Pharmacol Physiol. (1998) 25:561–7. doi: 10.1111/j.1440-1618.1998.tb02383.x

Smith PM, Ferguson AV. Circulating signals as critical regulators of autonomic state–central roles for the subformal organ. Am J Physiol Regul Integr Comp Physiol. (2010) 299:R405–15. doi: 10.1152/ajpregu.00140.2010

McKinley AV, Beckmann LM, Fisher JT. Effects of subformal organ stimulation on respiration in the anesthesitized rat. Can J Physiol Pharmacol. (1987) 65:1097–101. doi: 10.1139/p87-189

Wei S-G, Zhang Z-H, Beltz TG, Yu Y, Johnson AK, Felder RB. Subformal organ mediates sympathetic and hemodynamic responses to bloodborne proinflammatory cytokines. Hypertens. (2013) 62:18–25. doi: 10.1111/HYP.12140

McKinley MJ, Winter A, Ahlbrand R, Wilson A, Shukla S, Sah R. Subformal organ interleukin 1 receptor: a novel regulator of spontaneous and conditioned fear associated behaviors in mice. Brain Behav Immun. (2022) 101:304–17. doi: 10.1016/j.bbi.2021.02.004

McKinley MJ, Winter A, Ahlbrand R, Wilson A, Shukla S, Sah R. Interleukin 1 receptor within the subformal organ regulates spontaneous and conditioned fear. Brain Behav Immun. (2021) 98:34. doi: 10.1016/j.bbi.2021.08.131
154. Miselis RR. The efferent projections of the subfornical organ of the rat: a circumventricular organ within a neural network subserving water balance. Brain Res. (1981) 223:1–13. doi: 10.1016/0006-8993(81)90799-7

155. Swanson LW, Lind RW. Neural projections subserving the initiation of a specific motivated behavior in the rat: new projections from the subfornical organ. Brain Res. (1986) 379:399–403. doi: 10.1016/0006-8993(86)90799-7

156. Griez EJ, Colasanti A, van Dixt R, Salamon E, Schruers K. Carbon dioxide inhalation induces dose-dependent and age-related negative affectivity. PLoS One. (2007) 2:e987. doi: 10.1371/journal.pone.0000987

157. Gorman JM, Kent J, Martinez J, Bowse S, Coplan J, Papp LA. Physiological changes during carbon dioxide inhalation in patients with panic disorder, major depression, and premenstrual dysphoric disorder: evidence for a central fear mechanism. Arch Gen Psychiatry. (2001) 58:125–31. doi: 10.1001/archpsyc.58.2.125

158. Battaglia M, Ogliari A, D’Amato F, Kinkel R. Early-life risk factors for panic and separation anxiety disorder: insights and outstanding questions arising from human and animal studies of CO2 sensitivity. Neurosci Biobehav Rev. (2014) 46:655–64. doi: 10.1016/j.neubiorev.2014.04.005

159. Battaglia M, Marco B. Gene-environment interaction in panic disorder and posttraumatic stress disorder. Can J Psychiatry. (2013) 58:69–75. doi: 10.1177/07067437135080029

160. Battaglia M, Khan WU. Reappraising preclinical models of separation anxiety disorder, panic disorder, and CO2 sensitivity: implications for methodology and translation into new treatments. Curr Top Behav Neurosci. (2018) 40:195–217. doi: 10.1007/7854_2018_42

161. Battaglia M, Pesenti-Gritt P, Medland SE, Ogliari A, Tams K, Spatola CAM. A genetically informed study of the association between childhood separation anxiety, sensitivity to CO2, panic disorder, and the effect of childhood parental loss. Arch Gen Psychiatry. (2009) 66:64–71. doi: 10.1001/archgenpsychiatry.2008.513

162. Ogliari A, Tams K, Harris JR, Scaini S, Maffi C, Reichborn-Kjennerud T, et al. The relationships between adverse events, early antecedents, and carbon dioxide reactivity as an intermediate phenotype of panic disorder: a general population study. Psychosom Psychosom. (2010) 79:48–55. doi: 10.1016/j.psyphos.2009417

163. Cittaro D, Lampia V, Luchetti A, Coccurello R, Guaffini A, Felsani A, et al. Histone Modifications in a mouse model of early adversities and panic disorder: role for Asci1 and neurodevelopmental genes. Sci Rep. (2016) 6:25315. doi: 10.1038/srep25315

164. Luchetti A, Oddi D, Lampis V, Centofante E, Felsani A, Battaglia M, et al. Early handling and repeated cross-fostering have opposite effect on mouse emotionality. Front Behav Neurosci. (2015) 9:93. doi: 10.3389/fnb.2015.00093

165. Kinkel R, Gulemetova R. Neonatal maternal separation and neuroendocrine programming of the respiratory control system in rats. Biol Psychol. (2010) 84:26–38. doi: 10.1016/j.biopsycho.2009.09.001

166. Giannese F, Luchetti A, Barbiera G, Lampis V, Zanettini C, Knudsen GP, et al. Conserved DNA methylation signatures in early maternal separation and in nonspecific host response to pathogens. Nat Genet. (2018) 50:251–8. doi: 10.1038/s41588-018-0064-2

167. Battaglia M, Marco B. Genetic risk factors for depression-cardiovascular disease comorbidity. Neuropsychopharmacology. (2017) 42:46–61. doi: 10.1038/npp.2016.102

168. Takahashi A, Flanigan ME, McEwen BS, Russo SJ. Aggression, social stress, and the immune system in humans and animal models. Front Behav Neurosci. (2018) 12:56. doi: 10.3389/fnbeh.2018.00056

169. Ramirez K, Fornaguera-Trias J, Sheridan JF. Stress-induced microglia activation and monocyte trafficking to the brain underlie the development of anxiety and depression. Curr Top Behav Neurosci. (2017) 31:155–72. doi: 10.1007/7854_2016_25

170. Weber MD, Godbout JP, Sheridan JF. Repeated social defeat, neuroinflammation, and behavior: monocytes carry the signal. Neuropsychopharmacology. (2017) 42:46–61. doi: 10.1038/npp.2016.102

171. Rached K, Al-Abed AM, Elsaied M, Elsayed M, Elsayed S, et al. The role of social stress in mice. Nat Commun. (2015) 6:25131. doi: 10.1038/srep25131

172. Rached K, Al-Abed AM, Elsaied M, Elsayed S, et al. Individual differences in the peripheral immune system promote resilience and cognitive deficits after chronic social stress. Mol Psychiatry. (2021) 26:4770–82. doi: 10.1038/s41380-020-0788-3

173. McKim DB, Weber MD, Niraula A, Sawicki CM, Liu X, Jarrett BL, et al. Microglial receptor-1-type-1 on endothelial cells attenuated stress-induced neuroinflammation and prevented anxiety-like behavior. J Neurosci. (2014) 34:2583–91. doi: 10.1523/JNEUROSCI.1810-13.2014

174. Wohleb ES, Djem N, D’Amato F, Boulat G, Liu X, Cavanagh CM, et al. The effects of early-life stress on hippocampal neurons drives social withdrawal and cognitive deficits after chronic social stress. Mol Psychiatry. (2021) 26:4770–82. doi: 10.1038/s41380-020-0788-3

175. Wohleb ES, Djem N, D’Amato F, Boulat G, Liu X, Cavanagh CM, et al. The effects of early-life stress on hippocampal neurons drives social withdrawal and cognitive deficits after chronic social stress. Mol Psychiatry. (2021) 26:4770–82. doi: 10.1038/s41380-020-0788-3

176. Kim DB, Weber MD, Niraula A, Sawicki CM, Liu X, Jarrett BL, et al. Microglial activation, and anxiety. Neuroscience. (2015) 289:429–42. doi: 10.1016/j.neuroscience.2015.01.001

177. Wohleb ES, Djem N, D’Amato F, Boulat G, Liu X, Cavanagh CM, et al. The effects of early-life stress on hippocampal neurons drives social withdrawal and cognitive deficits after chronic social stress. Mol Psychiatry. (2021) 26:4770–82. doi: 10.1038/s41380-020-0788-3

178. Wohleb ES, Djem N, D’Amato F, Boulat G, Liu X, Cavanagh CM, et al. The effects of early-life stress on hippocampal neurons drives social withdrawal and cognitive deficits after chronic social stress. Mol Psychiatry. (2021) 26:4770–82. doi: 10.1038/s41380-020-0788-3

179. Wohleb ES, Djem N, D’Amato F, Boulat G, Liu X, Cavanagh CM, et al. The effects of early-life stress on hippocampal neurons drives social withdrawal and cognitive deficits after chronic social stress. Mol Psychiatry. (2021) 26:4770–82. doi: 10.1038/s41380-020-0788-3
Rag2-/- mice. anxiolytic and antidepressant-like effects, but enhance fear memory processes in Stress.  
Front Behav Neurosci. (2020) 17:1–16. doi: 10.1186/s12974-020-01842-0  

Careaga MBL, Girardi CEN, Suchecki D. Understanding posttraumatic stress disorder through fear conditioning, extinction and reconsolidation. Neurosci Biobehav Rev. (2016) 71:48–57. doi: 10.1016/j.neubiorev.2016.08.023  

Maren S, Holmes A. Stress and fear extinction. Neuropsychopharmacology. (2016) 41:58–79. doi: 10.1038/npp.2015.180  

Singewald N, Hauschild M, Sartori SB, Muigm P, Landgraf R, Hefner K, et al. Rodent models of impaired fear extinction: therapeutic approaches. Eur Neuropsychopharmacol. (2018) 21:5224–8. doi: 10.1016/j.euro.2018.05.052  

Yu Z, Fukushima H, Ono C, Sakai M, Kasahara Y, Kikuchi Y, et al. Microglial production of TNF-alpha is a key element of sustained fear memory. Brain Behav Neurosci. (2017) 59:313–21. doi: 10.1016/j.neubiorev.2016.08.011  

Dong Y, Li S, Lu Y, Li X, Liao Y, Peng Z, et al. Stress-induced NR1P3 inflammation activation negatively regulates fear memory in mice. J Neuroinflammation. (2020) 17:1–16. doi: 10.1186/s12974-020-01842-0  

Clark SM, Sorsa JA, Song C, Li X, Tonelli LH. CD4 + T cells confer anxiolytic and antidepressant-like effects, but enhance fear memory processes in Rag2⁻/⁻ mice. Brain Behav. (2019) 9:303–11. doi: 10.1080/10253890.2016.1191466  

Conoscenti MA, Fanselow MS. Dissociation in effective treatment and behavioral phenotype between stress-enhanced fear learning and learned helplessness. Front Behav Neurosci. (2019) 13:104. doi: 10.3389/fnbeh.2018.00114  

Rau V, Fanselow MS. Exposure to a stressor produces a long lasting enhancement of fear learning in rats. Stress. (2009) 12:335–33. doi: 10.1080/10253890802137520  

Jones ME, Lebonville CL, Barrus D, Lysle DT. The role of brain interleukin-1 in stress-enhanced fear learning. Neuropsychopharmacology. (2015) 40:1289–96. doi: 10.1038/npp.2014.317  

Jones ME, Lebonville CL, Paniccia JE, Balentine ME, Reissner KJ, Lysle DT. Hippocampal interleukin-1 mediates stress-enhanced fear learning: a potential role for astrocyte-derived interleukin-1β. Brain Behav. (2018) 8:355–63. doi: 10.1002/brb3.1799  

Jones ME, Paniccia JE, Lebonville CL, Reissner KJ, Lysle DT. Chemogenetic manipulation of dorsal hippocampal astrocytes protects against the development of stress-enhanced fear learning. Neuroscience. (2018) 388:45–56. doi: 10.1016/j.neuroscience.2018.07.015  

Dion-Albert L, Cadoret A, Doney E, Kaufmann FN, Dudek KA, Daigle B, et al. Vascular and blood-brain barrier-related changes underlie stress responses and resilience in female mice and depression in human tissue. Nat Commun. (2022) 13:1–18.  

Wang X, Ma L, Luo Y, Yang X, Upreti B, Cheng Y, et al. Increasing of blood brain barrier permeability and the association with depression and anxiety in systemic lupus erythematosus patients. Front Physiol. (2022) 9:852835. doi: 10.3389/fphys.2022.852835  

M. The inflammasome and danger associated molecular patterns (DAMPs) are involved in the response in adult rats. J Neuroinflammation. (2018) 15:224–8. doi: 10.1186/s12974-018-1304-7  

Bakker JM, Kavelaars A, Kamphuis PJGH, Heijnen CJ, Van Bel F. Effects immediately after birth induces a permanent microbiota shift that is shaped by the nursing mother. Microbiome. (2016) 3:1–10.  

Bakker JM, Kavelaars P, Amjid P, Colabelli P, van Vught H, van Bel F, et al. Neonatal dexamethasone treatment increases susceptibility to experimental autoimmune disease in adult rats. J Immunol. (2000) 165:5932–7. doi: 10.4049/jimmunol.165.9.5932  

Lubach GR, Coe CL, Ershler WB. Effects of early rearing environment on immune-responses of infant rhesus monkeys. Brain Behav. Immun. (1995) 9:3–46.  

Roque S, Mesquita AR, Palha JA, Sousa N, Correia-Neves M. The behavioral and immunological impact of maternal separation: a matter of timing. Front Behav Neurosci. (2014) 8:1–10.  

Bakker JM, Kavelaars P, Amjid P, Colabelli P, van Vught H, van Bel F, et al. Neonatal dexamethasone treatment on susceptibility to experimental autoimmune encephalomyelitis (EAE) and on the LPS-induced corticosterone response in adult rats. Oed todyssey. (1999) 45:48.  

Daft G, Pracek T, Kumar R, Morrow C, Lorenz RG. Cross-fostering immediately after birth induces a permanent microbiota shift that is shaped by the nursing mother. Microbiome. (2015) 3:1–10.  

Bartolomucci A, Gioiosa L, Chirieleonis A, Ceresini G, Parmigiani S, Palanza P. Cross fostering in mice: behavioral and physiological carry-over effects in adulthood. Genes Brain Behav. (2004) 3:115–22.  

Maslanik T, Mahaffey L, Tannura K, Beninson L, Greenwood B, Fleshner M. The inflammasome and danger associated molecular patterns (DAMPs) are implicated in cytokine and chemokine responses following stress exposure. Brain Behav. Immun. (2013) 28:54–62.  

Azzinnari D, Sigrist H, Stahlh D, Palme R, Hildebrand T, Leparc G, et al. Mouse social stress induces increased fear conditioning, helplessness and fatigue to physical challenge together with markers of altered immune and dopamine function. Neuropsychopharmacology. (2014) 85:328–41.